Lupin names president for Lupin-Somerset division
BALTIMORE and MUMBAI — Lupin on Wednesday announced the appointment of Dr. Kurt Nielsen as president of Lupin-Somerset.
Nielsen will be in charge of overall operations of the Gavis-Novel Somerset business and will be based out of Somerset, N.J.
"Kurt joins us at an exciting phase of Lupin's evolution as a global generics powerhouse and an emerging specialty pharmaceutical company, having closed the Gavis acquisition recently," said Vinita Gupta, CEO, Lupin Limited. "We have ambitious plans to further strengthen and expand our generic as well as specialty business in the U.S. I am confident that Kurt's leadership, knowledge and rich experience will help accelerate growth momentum and meet and exceed the ambitious targets that we have set for ourselves. We are delighted to have Kurt join the Lupin family."
Nielsen has more than 20 years of rich experience in creating, managing high growth businesses; research, development and launching new products in the U.S.; and managing transactions and business development.
Nielsen joins Lupin from Sandoz, where he held dual responsibility of being the global head of product development as well as being the VP of U.S. product development, portfolio and launch management for generic and brand products.
Having started his pharmaceutical career at Johnson & Johnson, Nielsen's previous leadership roles include being the chief technology officer & SVP at Catalent Pharma Solutions, responsible for their global R&D efforts; SVP in-charge of R&D, technology, including manufacturing and quality at URL Mutual Pharmaceuticals; and being the ED of generic R&D at TEVA Pharmaceuticals.
He holds a Ph.D in Chemistry from the Villanova University and has a BS in Chemistry from the University of Delaware.